Janssen Pharmaceutical has secured funding from NHS England to develop Symtuza for the treatment of HIV type-1 infection in patients aged 12 and above.

Symtuza is a single-tablet regimen and a fixed-dose combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF). The drug was approved by the European Union in September 2017.

Janssen is a pharmaceutical company based in Belgium, while NHS is an executive non-departmental public body of UK’s Department of Health and Social Care.

The funding will enable Janssen to provide Symtuza to clinicians across the UK, who can prescribe the drug to patients in need of treatment.

Novartis has signed an agreement with Cellular Biomedicines, under which the latter will manufacture the former’s CAR-T therapy Kymriah in China.

Novartis will invest $40m to gain a 9% stake in Cellular at $27.43 a share, and will have rights to certain technologies used to manufacture CAR-T therapies, while Cellular will receive net sales royalties on the product sales, under the agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cellular will be responsible for manufacturing Kymriah, while Novartis will handle the distribution, regulatory and commercialisation activities.

Based in the US, Cellular is a clinical-stage biopharmaceutical company, while Novartis is a pharmaceutical company based in Switzerland.

The agreement will enable Novartis to gain approval for Kymriah in China in accordance with the rules set by the Chinese Government.

“Novartis has signed an agreement with Cellular Biomedicines, under which the latter will manufacture the former’s CAR-T therapy Kymriah in China.”

Novo Nordisk has signed agreements with Glooko, Roche and DexCom with an aim to integrate its insulin pens with digital health technologies.

Novo Nordisk will integrate data from its NovoPen 6 and NovoPen Echo Plus insulin pens with Glooko’s open ecosystems and IBM Watson Health. It will also sync data with Roche’s mySugr and Accu-Chek Smart Pix diabetes management solutions and eventually with Dexcom’s continuous glucose monitoring (CGM) data.

The collaboration will enable Novo Nordisk to enhance the quality of care and develop sustainable healthcare solutions.

Based in Denmark, Novo Nordisk is a pharmaceutical company, while Dexcom and Glooko are US-based diabetes management solutions providers and Roche is a Switzerland-based healthcare company.

Norgine has completed the divestment of the Canadian assets of its subsidiary Merus Labs International to Searchlight Pharma for an undisclosed sum.

Searchlight Pharma will own the distribution and promotion rights for Enablex® and Vancocin®, while all non-Canadian assets will be retained by Norgine, as part of the transaction.

Based in the Netherlands, Norgine is a specialist pharmaceutical company, while Searchlight Pharma is a Canada-based specialist healthcare company.